Sona Nanotech Receives ‘Deprioritization’ from FDA; Health Canada Evaluation Continues

You may also like

Sona’s ‘THT’ Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its ‘THT’ Cancer Therapy

New NCL Assessment of Sona’s GNR Technology Highlights Process Improvement Success

Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device